Why Edwards Lifesciences Corporation (EW) stock moved
Edwards Lifesciences Corporation (EW) shares rose 4.1% to $89.28 as of September 17, 2026, a moderate gain from the prior close of $85.74. BestStocks flagged the session as a major change for EW. The move is tied to price move up. Below, we break down what changed for EW, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
EW climbed 4.1% to $89.28
EW rose 4.1% in its latest session, moving from $85.74 to $89.28.
What it means for Edwards Lifesciences Corporation investors
For Edwards Lifesciences Corporation investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 4.1% session move. Weighing against that: Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified; Edwards Lifesciences Corporation (EW) moved -3.13% from $90.09 to $87.27 on 2026-07-15. Wall Street's consensus price target sits at $101.70, implying +13.9% upside from $89.28. Over the past 90 days analysts logged 1 upgrade and 0 downgrades. BestStocks rates the overall signal quality low (55/100). With earnings roughly 42 days out, the next report is the most likely near-term test of the move.
EW price reaction
EW last traded at $89.28, up $3.54 (+4.13%) from the previous close of $85.74. The session traded on 1.1× average volume (normal), so participation was unremarkable. Over the past month the stock has ranged between $84.37 and $92.28, and it currently sits about 62% of the way up that band.
Bullish and bearish analyst opinions on Edwards Lifesciences Corporation (EW)
The consensus analyst price target on Edwards Lifesciences Corporation (EW) is $101.70, 13.9% above the recent $89.28. Over the past 90 days analysts logged 1 upgrade, 9 maintains, and 0 downgrades. Here is how the bullish and bearish cases on EW line up.
The bullish case
- Wall Street's consensus price target of $101.70 implies +13.9% upside from $89.28.
- The Street's most bullish target is $110.00 (+23.2%).
- 1 analyst upgrade in the past 90 days, most recently Leerink Partners to Outperform (2026-07-24).
- Material positive event.
- Positive 4.1% session move.
The bearish case
- The most bearish analyst target is $85.00 (-4.8%).
- Edwards Lifesciences declined 2.34% to $87.80 in early intraday trading with no major negative catalyst identified.
- Edwards Lifesciences Corporation (EW) moved -3.13% from $90.09 to $87.27 on 2026-07-15.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Sep 16, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for EW
Frequently asked questions about EW
Why did Edwards Lifesciences Corporation (EW) stock move?
EW rose 4.1% to $89.28. No single company-specific catalyst was confirmed during the move window, and it looks technical.
How much did EW stock rise?
EW gained 4.13% ($3.54) versus the prior close of $85.74, last trading at $89.28 on 1.1× average volume.
When is Edwards Lifesciences Corporation's next earnings date?
EW's next earnings report is estimated for 2026-10-29 — about 42 days away.
What is the analyst price target for EW?
The consensus analyst price target for EW is $101.70, about 13.9% above the current $89.28. Over the past 90 days, analysts recorded 1 upgrade, 9 maintains, and 0 downgrades.
How BestStocks tracks EW
This page is generated automatically by BestStocks' change-detection system after price move up was detected and verified against independent data sources. It draws on 20 tracked change events for EW, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of September 17, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.